Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Treasury Shares (2021 - 2025)

Historic Treasury Shares for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to $10514.0.

  • Verrica Pharmaceuticals' Treasury Shares changed 0.0% to $10514.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $10514.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $10514.0 for FY2024, which is 0.0% changed from last year.
  • Latest data reveals that Verrica Pharmaceuticals reported Treasury Shares of $10514.0 as of Q3 2025, which was down 0.0% from $10514.0 recorded in Q2 2025.
  • Verrica Pharmaceuticals' Treasury Shares' 5-year high stood at $475000.0 during Q2 2021, with a 5-year trough of $10514.0 in Q4 2023.
  • For the 5-year period, Verrica Pharmaceuticals' Treasury Shares averaged around $101600.4, with its median value being $105144.0 (2021).
  • Its Treasury Shares has fluctuated over the past 5 years, first surged by 30420.76% in 2022, then plummeted by 9752.61% in 2023.
  • Verrica Pharmaceuticals' Treasury Shares (Quarter) stood at $105144.0 in 2021, then surged by 304.21% to $425000.0 in 2022, then tumbled by 97.53% to $10514.0 in 2023, then changed by 0.0% to $10514.0 in 2024, then changed by 0.0% to $10514.0 in 2025.
  • Its Treasury Shares stands at $10514.0 for Q3 2025, versus $10514.0 for Q2 2025 and $10514.0 for Q1 2025.